Provexis PLC (PXS)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
0.45p
Buy
0.545p
-0.001p (-0.20%)
Provexis PLC is engaged in developing and licensing the proprietary Fruitflow, which is a heart-health functional food ingredient for the functional food sector.
Prices updated at 29 May 2025, 12:55 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Mr. Charles Dawson Buck
CEO
-
Most recent earnings
31 Mar 2024
Fiscal year end
31 Mar 2024
Employees
-
Head office
2 Blagrave Street
Reading
United Kingdom
RG1 1AZ
Key personnel
| Owner name | Salary | Bonus | All other compensation | Total compensation | Restricted stock award |
|---|---|---|---|---|---|
Mr. Charles Dawson Buck Non-Executive Director, Chairman | - | - | - | - | - |
Dr. Niamh Ann O'Kennedy Executive Director, Chief Scientific Officer | - | - | - | - | - |
Mr. Ian Ford Executive Director, CFO, CEO and Secretary | - | - | - | - | - |
Top 5 shareholders
| Owner name | No. of shares | Share as % of port. | Last change | Portfolio % change | Date of portfolio | % Total assets |
|---|---|---|---|---|---|---|
| No data | ||||||
Director dealings
| Date | Action | Name | Price | Value | No. of shares | Holding (%) | Additional info |
|---|---|---|---|---|---|---|---|
| No data | |||||||
Please note that past performance is not a reliable indicator of future returns.
